BioNTech SE Acquires InstaDeep Ltd.
January 10, 2023
BioNTech SE has agreed to acquire the remaining shares of InstaDeep Ltd. for approximately £362 million in cash and BioNTech shares, with up to ~£200 million of additional performance-based milestone payments. The acquisition brings roughly 240 AI, ML and software professionals into BioNTech to accelerate AI-driven drug discovery, embed InstaDeep’s DeepChain platform in BioNTech’s discovery pipeline, and expand BioNTech’s global AI capabilities.
- Buyers
- BioNTech SE
- Targets
- InstaDeep Ltd.
- Sellers
- InstaDeep shareholders
- Industry
- AI & Machine Learning
- Location
- England, United Kingdom
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Intellistake Technologies to Acquire NanoAi Technologies in C$17 Million Stock Deal
August 14, 2026
AI & Machine Learning
Intellistake Technologies Corp. has entered into a definitive agreement to acquire NanoAi Technologies Inc. for approximately C$17 million in Intellistake common shares. The transaction is intended to combine Intellistake’s AI/data infrastructure and enterprise SaaS capabilities with NanoAi’s portable standoff threat detection “sensor-to-decision” platform.
-
Merck KGaA to Acquire Bio-Techne for $11.3 Billion
June 25, 2026
Healthcare Services
Merck KGaA has entered a definitive agreement to acquire Bio-Techne for $73 per share in an all-cash transaction valued at about $11.3 billion (enterprise value). The deal is expected to close in late 2026 or early 2027, subject to regulatory approvals and Bio-Techne shareholder approval.
-
AI/ML Innovations Inc. Acquires Quantum Sciences Ltd
December 10, 2024
AI & Machine Learning
AI/ML Innovations Inc. entered into a binding share purchase agreement to acquire all issued and outstanding shares of Quantum Sciences Ltd for a purchase price of $690,000 to be paid by the issuance of 10,000,000 common shares. The acquisition (SPA dated December 9, 2024) brings digital health AI/ML and quantum‑inspired capability into AI/ML Innovations' portfolio and remains subject to customary closing conditions and CSE approval.
-
Genmab to Acquire ProfoundBio for $1.8 Billion
April 3, 2024
Biotechnology
Genmab (Nasdaq: GMAB) and ProfoundBio announced a definitive agreement for Genmab to acquire ProfoundBio in an all-cash transaction valued at $1.8 billion. The deal will expand Genmab’s mid- to late-stage oncology pipeline by adding ProfoundBio’s next-generation antibody-drug conjugate (ADC) programs, including Rina-S.
-
Meltwater Acquires DeepReason.ai
November 19, 2021
AI & Machine Learning
Meltwater B.V. has acquired Oxford University spin-out DeepReason.ai for $7.3 million in cash and Meltwater equity (including milestone/retention-based earn-outs). The acquisition brings DeepReason.ai's knowledge-graph reasoning technology and its team (five full-time and four part-time employees) into Meltwater to accelerate expansion of Meltwater's knowledge graph and AI-driven insights capabilities.
-
RadNet Acquires DeepHealth to Expand AI Capabilities
March 11, 2020
AI & Machine Learning
RadNet, Inc. has executed a definitive agreement to acquire DeepHealth, Inc., a Cambridge-based radiology AI and machine learning company focused on mammography and 3D breast imaging. The deal is structured as an initial share payment with up to additional milestone-based stock payments and aims to integrate DeepHealth's team and technology into RadNet's AI strategy to improve imaging interpretation and workflow efficiency.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.